ArticleCureus2024
Faecal Immunochemical Test (FIT) Value-Based Algorithm to Triage Symptomatic Colorectal Patients: A Retrospective Study From a Tertiary Care Hospital.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The aim was to evaluate the diagnostic accuracy of quantitative faecal immunochemical testing (FIT) in diagnosing colorectal cancer in symptomatic patients and using it to prioritize patients for urgent colorectal investigations. Methods A retrospective review was done of all symptomatic, FIT-positive patients referred from primary care to the colorectal clinic as per the National Institute for Health and Care Excellence (NICE) DG30 pathway from November 1, 2021, to February 11, 2022. Patients under 18 years of age were excluded. All patients were triaged to test (TTT) or booked in face-to-face (F2F) clinics according to a local algorithm. The data was collected in Microsoft Excel (Microsoft Corporation, Redmond, Washington, United States), and statistical analysis was performed using IBM SPSS Statistics for Windows (IBM Corp., Armonk, New York, United States). Results Out of 915 FIT-positive patients, 774 (84.5%) patients were TTT and 70 (7.65%) were booked in F2F clinics. The mean age was 71 years, and the majority were females (n=488 (F:M = 53:47)). However, a higher prevalence of positive FIT test was observed in men than in women at higher cut-off values of >100 and >200 μg Hb/g faeces (18.79 % vs 17.48% and 12.78% vs 11.69%, respectively). The number needed to scope was 10.8, 6.03, and 5.20 at cut-off values of ≥10, >100, and >200 μg Hb/g, respectively. At cut-off values of ≥10, >100, and >200 μg Hb/g, the specificity for colorectal cancer (CRC) with a 95% confidence interval (95% CI) was 63.75 %, 88.10%, and 92.27 %, respectively, and the positive predictive value (PPV) was 9.63, 18.20, and 21.24, respectively. The majority of the patients (30.9%) had no pathology on colonoscopy, whereas CRC was detected in 9.8%. Conclusion Quantitative FIT in symptomatic colorectal patients can be used to triage patients to investigations more appropriately, reducing the burden on outpatient and endoscopy units and improving the overall efficacy of health provision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.